1. Home
  2. CMPS vs NMRA Comparison

CMPS vs NMRA Comparison

Compare CMPS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPS
  • NMRA
  • Stock Information
  • Founded
  • CMPS 2020
  • NMRA 2019
  • Country
  • CMPS United Kingdom
  • NMRA United States
  • Employees
  • CMPS N/A
  • NMRA N/A
  • Industry
  • CMPS Biotechnology: Pharmaceutical Preparations
  • NMRA
  • Sector
  • CMPS Health Care
  • NMRA
  • Exchange
  • CMPS Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • CMPS 322.5M
  • NMRA 287.6M
  • IPO Year
  • CMPS 2020
  • NMRA 2023
  • Fundamental
  • Price
  • CMPS $2.79
  • NMRA $0.91
  • Analyst Decision
  • CMPS Strong Buy
  • NMRA Buy
  • Analyst Count
  • CMPS 7
  • NMRA 8
  • Target Price
  • CMPS $21.83
  • NMRA $10.14
  • AVG Volume (30 Days)
  • CMPS 1.0M
  • NMRA 1.2M
  • Earning Date
  • CMPS 05-07-2025
  • NMRA 03-03-2025
  • Dividend Yield
  • CMPS N/A
  • NMRA N/A
  • EPS Growth
  • CMPS N/A
  • NMRA N/A
  • EPS
  • CMPS N/A
  • NMRA N/A
  • Revenue
  • CMPS N/A
  • NMRA N/A
  • Revenue This Year
  • CMPS N/A
  • NMRA N/A
  • Revenue Next Year
  • CMPS N/A
  • NMRA N/A
  • P/E Ratio
  • CMPS N/A
  • NMRA N/A
  • Revenue Growth
  • CMPS N/A
  • NMRA N/A
  • 52 Week Low
  • CMPS $2.69
  • NMRA $0.90
  • 52 Week High
  • CMPS $10.31
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • CMPS 31.50
  • NMRA 23.28
  • Support Level
  • CMPS $2.88
  • NMRA $1.12
  • Resistance Level
  • CMPS $3.16
  • NMRA $1.13
  • Average True Range (ATR)
  • CMPS 0.21
  • NMRA 0.09
  • MACD
  • CMPS -0.03
  • NMRA 0.03
  • Stochastic Oscillator
  • CMPS 9.30
  • NMRA 2.47

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: